Effect of whole soy and purified daidzein on ambulatory blood pressure and endothelial function—a 6-month double-blind, randomized controlled trial among Chinese postmenopausal women with prehypertension
European Journal of Clinical Nutrition , (18 March 2015) | doi:10.1038/ejcn.2015.24
, , , , , and
Abstract
Background/objectives:
Although
observational studies suggest that soy foods or isoflavones are
cardio-protective, clinical trials on whole soy or isoflavone daidzein
(one major isoflavone and the precursor of equol) on blood pressure (BP)
and endothelial function (EF) are few and have not been specifically
conducted among equol producers, a population most likely to benefit
from soy treatment.
Subjects/Methods:
We
performed a 6-month double-blind, randomized, placebo-controlled trial
to examine the effect of whole soy (soy flour) or purified daidzein on
BP and EF in prehypertensive or untreated hypertensive postmenopausal
women verified to be equol producers. A total of 270 eligible women were
recruited and randomized to either one of the three treatment groups,
40 g soy flour (whole soy group), 40 g low-fat milk powder+63 mg daidzein (daidzein group) or 40 g
low-fat milk powder (active control group) daily, each given as a solid
beverage powder for 6 months. The primary outcome measures were 24 h ambulatory BP (ABP) and EF assessed by flow-mediated dilation using brachial artery ultrasound.
Results:
A
total of 253 subjects completed the study according to protocol.
Urinary isoflavones indicated good compliance with the interventions.
Intention to treat and per-protocol analysis indicated that there was no
significant difference in the 6-month changes or %
changes in parameters of ABP and brachial flow-mediated dilation among
the three treatment groups. A further subgroup analysis among
hypertensive women (n=138) did not alter the conclusions.
Conclusions:
Whole
soy and purified daidzein had no significant effect on BP and vascular
function among equol-producing postmenopausal women with prehypertension
or untreated hypertension.